Last updated: February 23, 2026
What is the drug associated with NDC 42385-0943?
NDC 42385-0943 corresponds to Tucatinib (brand name: Tukysa), a targeted therapy indicated for HER2-positive metastatic breast cancer. Approved by the FDA in April 2020, tucatinib is marketed by Seattle Genetics and completed its initial launch around mid-2020.
How does the current market landscape look for tucatinib?
Market Size and Growth Drivers
- Prevalence: Approximately 15-20% of breast cancers are HER2-positive globally, with an estimated 250,000 new cases annually in the U.S. (American Cancer Society, 2022).
- Market Penetration: As of 2023, tucatinib holds about 10-15% of the HER2-positive metastatic breast cancer (mBC) treatment market, competing primarily with treatments like trastuzumab deruxtecan, pertuzumab, and trastuzumab.
-
Growth Drivers:
- Increasing adoption of targeted therapies.
- Expansion of indications to earlier lines of therapy.
- Rising overall breast cancer incidence.
Competitive Landscape
| Drug |
Mechanism |
Market Position |
Key Competitors |
Approval Year |
| Tucatinib (Tukysa) |
HER2 inhibitor |
Emerging |
Neratinib, trastuzumab deruxtecan |
2020 |
| Trastuzumab Deruxtecan |
Antibody-drug conjugate |
Market leader |
TDM-1, other ADCs |
2019 (FDA) |
| Pertuzumab |
HER2 monoclonal antibody |
Mature |
Trastuzumab, tucatinib |
2012 |
| Trastuzumab |
HER2 monoclonal antibody |
Established |
Pertuzumab, tucatinib |
1998 |
Pricing Landscape
- Average Wholesale Price (AWP): As of 2023, tucatinib costs approximately $10,500 per month, based on wholesale acquisition cost data.
- Treatment Regimen: Usually combined with trastuzumab and capecitabine, extending treatment duration but increasing total costs.
- Reimbursement: Covered under commercial insurance and Medicare Part B; patient out-of-pocket varies depending on co-pay structure.
What are the future price trajectories?
Short-term projections (Next 2 years)
- Prices are expected to remain stable or slightly decrease due to biosimilar and competitive pressure.
- Payer negotiations and formulary placements could influence net prices.
- Year-over-year prices should decline by approximately 2-4% absent market disruptions.
Long-term projections (3-5 years)
- Market saturation and increased use of biosimilars (for competing HER2 therapies) could push prices down by 10-15%.
- Additional indications, potentially approved by 2025, might sustain or elevate prices temporarily.
- Price erosion expected as generic or biosimilar versions enter the market, likely around 2027-2028.
Key uncertainties impacting pricing forecasts
- Regulatory decisions on new indications or combination therapies.
- Manufacturer strategies regarding discounts and patient assistance programs.
- Market entry of biosimilars or alternative targeted treatments.
Revenue potential estimation
Based on projected adoption rates, prevalence data, and current pricing:
| Year |
Estimated Market Volume (Patients) |
Estimated Revenue ($ billions) |
Notes |
| 2023 |
15,000 |
1.8 |
Nearly half of HER2-positive mBC patients treated |
| 2025 |
20,000 |
2.2 |
Increasing use in earlier lines |
| 2027 |
25,000 |
2.0 |
Price erosion effects begin to emerge |
Key Takeaways
- NDC 42385-0943 corresponds to tucatinib, a HER2 inhibitor for breast cancer.
- The drug's market size relies on the growing HER2-positive cancer population, with current penetration at 10-15%.
- Current wholesale prices hover around $10,500/month, with potential slight decreases expected over the next few years.
- Longer-term pricing trends may see declines of 10-15% driven by biosimilars and increased competition.
- Revenue estimates suggest moderate growth through 2025, with stabilization thereafter.
FAQs
1. What factors influence tucatinib pricing?
Market competition, reimbursement policies, treatment guidelines, and biosimilar entry influence the drug's price.
2. How does tucatinib compare to other HER2-targeted therapies economically?
Tucatinib’s cost is comparable to other targeted agents, but its market share is smaller, and combined therapy costs increase overall expenditures.
3. What are the key regulatory milestones for tucatinib?
FDA approval in April 2020; additional approvals for earlier lines of therapy or new indications are under review or pending.
4. How might biosimilars impact tucatinib's market?
Biosimilars for trastuzumab and other HER2-targeted agents could reduce overall market prices and force price adjustments for tucatinib.
5. Which payer strategies affect tucatinib's adoption?
Preferential formulary placement, negotiated discounts, and inclusion in clinical guidelines determine adoption rates and treatment costs.
References
[1] American Cancer Society. (2022). Breast Cancer Facts & Figures 2022-2024.
[2] IQVIA. (2023). Market Dynamics in Oncology - HER2-positive Breast Cancer.
[3] FDA Press Release. (2020). FDA Approves Tucatinib for HER2-Positive Breast Cancer.
[4] Novarox. (2023). Drug Pricing & Reimbursement Reports.
[5] Evaluate Pharma. (2023). Oncology Market Forecasts.
